• Je něco špatně v tomto záznamu ?

Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids

J. Donnez, R. Hudecek, O. Donnez, D. Matule, HJ. Arhendt, J. Zatik, Z. Kasilovskiene, MC. Dumitrascu, H. Fernandez, DH. Barlow, P. Bouchard, BC. Fauser, E. Bestel, P. Terrill, I. Osterloh, E. Loumaye,

. 2015 ; 103 (2) : 519-27.e3.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15022890

OBJECTIVE: To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg daily of ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. DESIGN: Double-blind, randomized administration of two 12-week courses of ulipristal acetate. SETTING: Gynecology centers. PATIENT(S): A total of 451 patients with symptomatic uterine fibroid(s) and heavy bleeding. INTERVENTION(S): Two repeated 12-week treatment courses of daily 5 or 10 mg of ulipristal acetate. MAIN OUTCOME MEASURE(S): Amenorrhea, controlled bleeding, fibroid volume, quality of life (QoL), pain. RESULT(S): In the 5- and 10-mg treatment groups (62% and 73% of patients, respectively) achieved amenorrhea during both treatment courses. Proportions of patients achieving controlled bleeding during two treatment courses were >80%. Menstruation resumed after each treatment course and was diminished compared with baseline. After the second treatment course, median reductions from baseline in fibroid volume were 54% and 58% for the patients receiving 5 and 10 mg of ulipristal acetate, respectively. Pain and QoL improved in both groups. Ulipristal acetate was well tolerated with less than 5% of patients discontinuing treatment due to adverse events. CONCLUSION(S): Repeated 12-week courses of daily oral ulipristal acetate (5 and 10 mg) effectively control bleeding and pain, reduce fibroid volume, and restore QoL in patients with symptomatic fibroids. CLINICAL TRIAL REGISTRATION NUMBER: NCT01629563 (PEARL IV).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15022890
003      
CZ-PrNML
005      
20150728110635.0
007      
ta
008      
150709s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.fertnstert.2014.10.038 $2 doi
035    __
$a (PubMed)25542821
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Donnez, Jacques $u Société de Recherche pour l'infertilité, Brussels, Belgium. Electronic address: jacques.donnez@gmail.com.
245    10
$a Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids / $c J. Donnez, R. Hudecek, O. Donnez, D. Matule, HJ. Arhendt, J. Zatik, Z. Kasilovskiene, MC. Dumitrascu, H. Fernandez, DH. Barlow, P. Bouchard, BC. Fauser, E. Bestel, P. Terrill, I. Osterloh, E. Loumaye,
520    9_
$a OBJECTIVE: To investigate the efficacy and safety of repeated 12-week courses of 5 or 10 mg daily of ulipristal acetate for intermittent treatment of symptomatic uterine fibroids. DESIGN: Double-blind, randomized administration of two 12-week courses of ulipristal acetate. SETTING: Gynecology centers. PATIENT(S): A total of 451 patients with symptomatic uterine fibroid(s) and heavy bleeding. INTERVENTION(S): Two repeated 12-week treatment courses of daily 5 or 10 mg of ulipristal acetate. MAIN OUTCOME MEASURE(S): Amenorrhea, controlled bleeding, fibroid volume, quality of life (QoL), pain. RESULT(S): In the 5- and 10-mg treatment groups (62% and 73% of patients, respectively) achieved amenorrhea during both treatment courses. Proportions of patients achieving controlled bleeding during two treatment courses were >80%. Menstruation resumed after each treatment course and was diminished compared with baseline. After the second treatment course, median reductions from baseline in fibroid volume were 54% and 58% for the patients receiving 5 and 10 mg of ulipristal acetate, respectively. Pain and QoL improved in both groups. Ulipristal acetate was well tolerated with less than 5% of patients discontinuing treatment due to adverse events. CONCLUSION(S): Repeated 12-week courses of daily oral ulipristal acetate (5 and 10 mg) effectively control bleeding and pain, reduce fibroid volume, and restore QoL in patients with symptomatic fibroids. CLINICAL TRIAL REGISTRATION NUMBER: NCT01629563 (PEARL IV).
650    _2
$a aplikace orální $7 D000284
650    _2
$a dospělí $7 D000328
650    _2
$a amenorea $x diagnóza $x farmakoterapie $7 D000568
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a bolesti hlavy $x chemicky indukované $x diagnóza $7 D006261
650    _2
$a lidé $7 D006801
650    _2
$a leiomyom $x diagnóza $x farmakoterapie $7 D007889
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nauzea $x chemicky indukované $x diagnóza $7 D009325
650    _2
$a norpregnadieny $x aplikace a dávkování $x škodlivé účinky $7 D009649
650    _2
$a bolest $x diagnóza $x farmakoterapie $7 D010146
650    12
$a kvalita života $7 D011788
650    _2
$a výsledek terapie $7 D016896
650    _2
$a nádory dělohy $x diagnóza $x farmakoterapie $7 D014594
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hudecek, Robert $u Department of Obstetrics and Gynaecology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
700    1_
$a Donnez, Olivier $u Institut de Recherche Expérimentale et Clinique (IREC), Université de Louvain, Centre Hospitalier Université (CHU) Université Catholique de Louvain (UCL) Mont-Godinne Dinant, Yvoir, Belgium.
700    1_
$a Matule, Dace $u Medical Company ARS Gynaecology, Department No.5, Riga, Latvia.
700    1_
$a Arhendt, Hans-Joachim $u Praxis für Frauenheilkunde, Klinische Forschung und Weiterbildung, Magdeburg, Germany. $7 gn_A_00008360
700    1_
$a Zatik, Janos $u Szent Anna Szuleszeti, Nogyogyaszati es Ultrahang Maganrendelo, Debrecen, Hungary.
700    1_
$a Kasilovskiene, Zaneta $u Private Clinic "Maxmeda" Vilnius, Lithuania.
700    1_
$a Dumitrascu, Mihai Cristian $u Centrul Medical EUROMED SRL, Obstetrica-Ginecologie, Bucuresti, Romania.
700    1_
$a Fernandez, Hervé $u Hôpital Bicêtre-Assistance Publique-Hopitaux de Paris (APHP), Service de Gynécologie-Obstétrique, Le Kremlin, Bicêtre cedex, France.
700    1_
$a Barlow, David H $u Hamad Medical Corporation, Women's Health Services, Qatar.
700    1_
$a Bouchard, Philippe $u Service d'Endocrinologie, Hôpital Saint-Antoine, Paris, France.
700    1_
$a Fauser, Bart C J M $u Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, Utrecht, the Netherlands.
700    1_
$a Bestel, Elke $u PregLem S.A., Plan-les-Ouates, Geneva, Switzerland.
700    1_
$a Terrill, Paul $u CROS NT Limited, Maidenhead.
700    1_
$a Osterloh, Ian $u OsterMed Ltd., Birmingham, United Kingdom.
700    1_
$a Loumaye, Ernest $u ObsEva SA, Plan-les-Ouates, Geneva, Switzerland.
773    0_
$w MED00001795 $t Fertility and sterility $x 1556-5653 $g Roč. 103, č. 2 (2015), s. 519-27.e3
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25542821 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150728110720 $b ABA008
999    __
$a ok $b bmc $g 1083229 $s 905883
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 103 $c 2 $d 519-27.e3 $i 1556-5653 $m Fertility and sterility $n Fertil Steril $x MED00001795
LZP    __
$a Pubmed-20150709
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace